Hui Feng, MD, PhD
Assistant Professor
Boston University School of Medicine
Dept of Pharmacology & Experimental Therapeutics

MD, Beijing Medical University
PhD, University of Georgia
MS, Peking Union Medical College

Cancer Research: Dr. Feng is Director of the Laboratory of Zebrafish Genetics and Cancer Therapeutics. Dr. Feng’s research interests focus on identifying novel genes and pathways that are essential for MYC-related tumor transformation and progression, particularly for T-Lymphoblastic Lymphoma/Leukemia, Neuroblastoma and Breast Cancer. The research strategy of Dr. Feng’s research is to combine the analysis of human cancer cells with the genetic and imaging capacities of the zebrafish system.

Current research areas in Dr. Feng’s laboratory include:
1) To determine the molecular mechanisms underlying tumor cell intravasation and tumor progression.
2) To identify novel genes and pathways that, when mutated, delay the initiation and progression of MYC-related cancers.
3) To test the identified genes’ therapeutic potential in treating MYC-related cancers and to characterize their molecular relevance to MYC.

The long-term goal of Dr. Feng’s research is to discover novel molecular therapies to target critical components of MYC-driven oncogenic pathways, thus providing treatment alternatives that are more specific and less toxic.

2014-2017 St. Baldrick's Foundation: St. Baldrick Career Development Award
2013-2014 Karin Grunebaum Cancer Research Foundation: Grunebaum Faculty Fellowship
2013-2016 Boston University: Ralph Edwards Career Development Professorship
2012-2015 National Cancer Institute: Howard Temin Pathway to Independence Award in Cancer Research (R00)
2012-2013 American Cancer Society : American Cancer Society pilot Award
2009-2010 Stahl Family Charitable Foundation: Stahl Family Charitable Foundation Award
2009-2011 National Cancer Institute: Howard Temin Pathway to Independence Award in Cancer Research (K99)
2008 Harvard Partners in Health: Partners in Excellence Award
2005-2005 Cancer Research Institute: Postdoctoral Fellowship Award
2005 American Association for Cancer Research: American Association for Cancer Research Award - declined
2005-2008 Leukemia and Lymphoma Society: Special Fellow Award

The Role of DLST in Leukemogenesis
08/07/2018 - 07/31/2023 (PI)
NIH/National Cancer Institute

Regulatory Role and Targetability of UFDI in MYC-drlven Leukemia
01/01/2018 - 12/31/2021 (PI)
American Cancer Society, Inc.

Targeting DLST as a novel therapeutic approach for neuroblastoma
07/01/2018 - 06/30/2019 (PI)
St. Baldrick's Foundation

The Role of DLST in Leukemogenesis
08/15/2017 - 07/31/2018 (PI)
NIH/National Cancer Institute

Targeting DLST as a novel therapeutic approach for neuroblastoma
07/01/2017 - 06/30/2018 (PI)
St. Baldrick's Foundation

Targeting Elevated S1P1 Signaling as a Novel Therapeutic Approach for Triple-Negative Breast Cancer
07/01/2016 - 06/30/2018 (PI)
The Mary Kay Foundation

Targeting DLST as a Novel Therapeutic Approach for Neuroblastoma
07/01/2014 - 06/30/2017 (PI)
St. Baldrick's Foundation

Dissecting the regulatory role of DLST in MYC-driven Leukemogenesis
07/01/2015 - 12/31/2016 (PI)
Leukemia Research Foundation

Oncorequisite Genes in MYC-mediated Transformation
04/01/2012 - 03/31/2015 (PI)
NIH/National Cancer Institute

Yr Title Project-Sub Proj Pubs
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Narasimhan S, Stanford Zulick E, Novikov O, Parks AJ, Schlezinger JJ, Wang Z, Laroche F, Feng H, Mulas F, Monti S, Sherr DH. Towards Resolving the Pro- and Anti-Tumor Effects of the Aryl Hydrocarbon Receptor. Int J Mol Sci. 2018 May 07; 19(5).View Related Profiles. PMID: 29735912.
  2. Lian H, Li D, Zhou Y, Landesman-Bollag E, Zhang G, Anderson NM, Tang KC, Roderick JE, Kelliher MA, Seldin DC, Fu H, Feng H. CK2 inhibitor CX-4945 destabilizes NOTCH1 and synergizes with JQ1 against human T-acute lymphoblastic leukemic cells. Haematologica. 2017 01; 102(1):e17-e21.View Related Profiles. PMID: 27758824; DOI: 10.3324/haematol.2016.154013;.
  3. Anderson NM, Li D, Peng HL, Laroche FJF, Mansour MR, Gjini E, Aioub M, Helman DJ, Roderick JE, Cheng T, Harrold I, Samaha Y, Meng L, Amsterdam A, Neuberg DS, Denton TT, Sanda T, Kelliher MA, Singh A, Look AT, and Feng H. The TCA Cycle Transferase DLST is Important for MYC-mediated Leukemogenesis. Leukemia. 2016.
  4. Harrison NR, Laroche FJ, Gutierrez A, Feng H. Zebrafish Models of Human Leukemia: Technological Advances and Mechanistic Insights. Adv Exp Med Biol. 2016; 916:335-69.View Related Profiles. PMID: 27165361; PMCID: PMC4933302; DOI: 10.1007/978-3-319-30654-4_15;.
  5. Harrold I, Carbonneau S, Moore BM, Nguyen G, Anderson NM, Saini AS, Kanki JP, Jette CA, Feng H. Efficient transgenesis mediated by pigmentation rescue in zebrafish. Biotechniques. 2016 Jan; 60(1):13-20. PMID: 26757807; PMCID: PMC4768720; DOI: 10.2144/000114368;.
  6. Srinivasan S, Chitalia V, Meyer RD, Hartsough E, Mehta M, Harrold I, Anderson N, Feng H, Smith LE, Jiang Y, Costello CE, Rahimi N. Hypoxia-induced expression of phosducin-like 3 regulates expression of VEGFR-2 and promotes angiogenesis. Angiogenesis. 2015 Oct; 18(4):449-62.View Related Profiles. PMID: 26059764; PMCID: PMC4600037; DOI: 10.1007/s10456-015-9468-3;.
  7. Huiting L, Laroche, FJF, Feng H. The Zebrafish as a Tool to Cancer Drug Discovery. Austin Journal of Pharmacology and Therapeutics. Austin Journal of Pharmacology and Therapeutics. Secaucus. 2015; 2(3):1069.
  8. Huiting LN, Laroche F, Feng H. The Zebrafish as a Tool to Cancer Drug Discovery. Austin J Pharmacol Ther. 2015; 3(2):1069.View Related Profiles. PMID: 26835511.
  9. Shivanna S, Harrold I, Shashar M, Meyer R, Kiang C, Francis J, Zhao Q, Feng H, Edelman ER, Rahimi N, Chitalia VC. The c-Cbl ubiquitin ligase regulates nuclear ß-catenin and angiogenesis by its tyrosine phosphorylation mediated through the Wnt signaling pathway. J Biol Chem. 2015 May 15; 290(20):12537-46.View Related Profiles. PMID: 25784557; PMCID: PMC4432275; DOI: 10.1074/jbc.M114.616623;.
  10. Gutierrez A, Feng H, Stevenson K, Neuberg DS, Calzada O, Zhou Y, Langenau DM, Look AT. Loss of function tp53 mutations do not accelerate the onset of myc-induced T-cell acute lymphoblastic leukaemia in the zebrafish. Br J Haematol. 2014 Jul; 166(1):84-90. PMID: 24690081; DOI: 10.1111/bjh.12851;.
Showing 10 of 23 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 23 publications over 13 distinct years, with a maximum of 4 publications in 2015 and 2016

In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Cancer Therapeutics
Tumor Intravasation

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Co-Mentor or Peer Mentor
  • Education Mentor
  • Research / Scholarly Mentor
  • Work / Life Integration Mentor
Contact for Mentoring:

72 E. Concord St Silvio Conte (K)
Boston MA 02118
Google Map

Feng's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department